News & Insights
Through the lens of precision medicine, all disease, no matter how common, is rare disease.
By Peter J. Embi, MD, MS, FACP, FACMI, Co-founder Signet Accel Practicing medicine today is increasingly reliant on the documentation, retrieval and use of vast amounts of clinical data. We manage medical information with computers, and electronic health records (and the time we spend on them) have become ubiquitous in our practices. The challenge, now, is to use it—fully and responsibly—so we might realize the potential of these rapidly-growing amounts of health data. Our aim is not only to improve care, but also to advance biomedical research and discovery, so that we can take better care of patients both now and into the future. Achieving this requires that we collect, integrate and analyze data, often across sites separated by geography and technology.
By Dr. Philip R. O. Payne, PhD, FACMI, Co-founder Signet Accel There have been a variety of publications and debates over the past several years arguing for the adoption of lessons learned from the private sector in order to increase the speed, scale, and scope of innovation in the healthcare and life sciences research communities. At their core, these arguments speak to the need to increase the agility and data-centricity of investigative efforts that seek to develop and disseminate new biomedical knowledge. However, when considering such a charge, a number of important questions come to mind, specifically: 1) can we map the role of a researcher to that of an entrepreneur, as one would find in the private sector; and 2) what are the foundational resources needed for such researchers to pursue their activities in a manner that is analogous to entrepreneurs in the private sector?
The biopharmaceutical industry is under tremendous pressure to deliver more robust research methodologies, investigate new treatments, and better understand (and predict) interactive affects for those with comorbidities and concomitant treatments. Yet, at the same time, an estimated 80% of healthcare data remains unstructured, and therefore locked and inaccessible.
COLUMBUS, Ohio--Signet Accel, a software and services company specializing in data integration and harmonization, today announced a partnership with online training provider Neunoia. Signet Accel customers can now access custom-built online training modules, on demand, from any location. E-learning with Neunoia will provide Signet Accel clients with convenient and thorough online training as they employ Avec®, Signet Accel’s commercial federated data integration platform that delivers true interoperability to big data in healthcare.
From Healthcare IT News: "LAS VEGAS – Signet Accel has launched Avec®, a commercial federated data integration platform designed to offer interoperability to healthcare organizations, the company announced at HIMSS16. Avec® enables analysis of complex, distributed healthcare data in a manner that is secure and protects the ownership and control of data at every site, Signet Accel said. It does not require changes in the process of collecting data, the manner in which data is stored, where data is stored or how data is structured, the vendor added."
The search for true interoperability can be time consuming, frustrating, and more often than not, confusing. Wide claims are often made about interoperability solutions, only to later find they aren’t truly interoperable. Oversold and under- delivered may be the industry norm, but it’s not a certainty. The best way to ensure you’re pleased with your interoperability solution is to ask the right questions from the start. Consider the below a primer on the three C’s to true interoperability: care, collaboration and cost.
In four short days, a small city will be born in Las Vegas. More than 40,000 health IT professionals, clinicians, executives and vendors will gather to network and learn with their peers from around the world at the Healthcare Information and Management Systems Society (HIMSS) Exhibition and Conference.